Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion
The deal aims to bolster Vertex's drug pipeline with Crinetics' specialized treatments.
Business & Markets • 3 months ago
Vertex Pharmaceuticals has announced plans to acquire Crinetics Pharmaceuticals in a deal valued at $10 billion. The acquisition is expected to enhance Vertex's existing drug pipeline and potentially increase its annual revenue by approximately $5 billion.
Crinetics Pharmaceuticals is known for its development of specialized drugs, including Palsonify and Atumelnant. The addition of these treatments to Vertex's portfolio is a key driver for the transaction, according to Vertex officials. The company anticipates that these drugs will contribute significantly to its revenue growth.